74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Madrigal Pharmaceuticals Inc
Closed
SectorHealthcare
319.23 3.48
Overview
Share price change
24h
Min
297.56
Max
319.84
Income | 48M -59M |
|---|---|
Sales | 41M 103M |
EPS | -2.71 |
Profit margin | -57.507 |
Employees | 528 |
EBITDA | 47M -56M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +34.03% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -365M 6.7B |
|---|---|
Previous open | 315.75 |
Previous close | 319.23 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Madrigal Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Madrigal Pharmaceuticals Inc Forecast
Price Target
By TipRanks
34.03% upside
12 Months Forecast
Average 413.87 USD 34.03%
High 539 USD
Low 239 USD
Based on 15 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
